Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ARQL

ArQule (ARQL) Stock Price, News & Analysis

ArQule logo

About ArQule Stock (NASDAQ:ARQL)

Key Stats

Today's Range
$20.00
$20.00
50-Day Range
$20.00
$20.00
52-Week Range
$3.15
$20.45
Volume
N/A
Average Volume
5.27 million shs
Market Capitalization
$2.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Receive ARQL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ArQule and its competitors with MarketBeat's FREE daily newsletter.

ARQL Stock News Headlines

Merck Sharp & Dohme Corp.'s Net Worth
ASCO Live Blog: Saturday
We recommended Nvidia in 2016, now we’re recommending this…
The AI boom is just getting started. And the real wealth has still to be made…
See More Headlines

ARQL Stock Analysis - Frequently Asked Questions

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company earned $0.21 million during the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative net margin of 805.61% and a negative trailing twelve-month return on equity of 33.10%.

Based on aggregate information from My MarketBeat watchlists, some other companies that ArQule investors own include Amarin (AMRN), Verastem (VSTM), Celldex Therapeutics (CLDX), Corbus Pharmaceuticals (CRBP), Advanced Micro Devices (AMD), Novavax (NVAX) and Axsome Therapeutics (AXSM).

Company Calendar

Last Earnings
10/30/2019
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARQL
CUSIP
04269E10
Fax
N/A
Employees
36
Year Founded
N/A

Profitability

Net Income
$-15,480,000.00
Net Margins
-805.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$25.76 million
Book Value
$0.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.42 billion
Optionable
Optionable
Beta
2.49
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ARQL) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners